share_log

国投证券4月25日发布研报称，给予百洋医药（301015.SZ）买入评级，目标价格为35.69元。评级理由主要包括：1）事件：公司发布2023年年报及2024年一季报，利润端实现快速增长；2）销售费用率持续优化，盈利能力有所提升；3）持续完善产品矩阵，创新药械有望陆兑现。（每日经济新闻）

SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 ann

Zhitong Finance ·  Apr 25 16:31
SDIC Securities released a research report on April 25 stating that Baiyang Pharmaceutical (301015.SZ) was given a purchase rating and the target price was 35.69 yuan. The main reasons for the rating include: 1) incident: the company released its 2023 annual report and 2024 quarterly report, and the profit side achieved rapid growth; 2) sales expenses continued to be optimized, and profitability improved; 3) Continued improvement of the product matrix, and innovative pharmaceutical devices are expected to be realized. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment